Janus Henderson Group PLC Acquires New Stake in MBX Biosciences, Inc. $MBX

Janus Henderson Group PLC bought a new stake in MBX Biosciences, Inc. (NASDAQ:MBX) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 10,300 shares of the company’s stock, valued at approximately $308,000.

Several other institutional investors and hedge funds have also bought and sold shares of MBX. California State Teachers Retirement System grew its stake in shares of MBX Biosciences by 1,197.9% during the 1st quarter. California State Teachers Retirement System now owns 22,765 shares of the company’s stock valued at $680,000 after purchasing an additional 21,011 shares during the period. Rock Springs Capital Management LP lifted its stake in shares of MBX Biosciences by 1.9% in the 1st quarter. Rock Springs Capital Management LP now owns 287,967 shares of the company’s stock worth $8,596,000 after purchasing an additional 5,343 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of MBX Biosciences by 30.3% in the first quarter. The Manufacturers Life Insurance Company now owns 90,634 shares of the company’s stock worth $2,705,000 after buying an additional 21,083 shares during the last quarter. Sei Investments Co. boosted its holdings in shares of MBX Biosciences by 17.4% in the first quarter. Sei Investments Co. now owns 8,989 shares of the company’s stock worth $268,000 after buying an additional 1,332 shares during the last quarter. Finally, Dimensional Fund Advisors LP bought a new stake in MBX Biosciences during the first quarter valued at approximately $1,396,000.

MBX Biosciences Price Performance

Shares of NASDAQ:MBX opened at $66.01 on Wednesday. MBX Biosciences, Inc. has a 1-year low of $9.63 and a 1-year high of $72.64. The company has a market capitalization of $3.18 billion, a P/E ratio of -27.39 and a beta of 0.10. The firm’s 50 day simple moving average is $53.62 and its two-hundred day simple moving average is $40.36.

MBX Biosciences (NASDAQ:MBX) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.10). On average, sell-side analysts anticipate that MBX Biosciences, Inc. will post -2.87 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on MBX shares. Mizuho increased their price target on shares of MBX Biosciences from $57.00 to $91.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. Citizens Jmp boosted their price objective on shares of MBX Biosciences from $76.00 to $86.00 and gave the company a “market outperform” rating in a research report on Tuesday, May 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MBX Biosciences in a report on Friday, July 17th. Truist Financial lifted their target price on MBX Biosciences from $70.00 to $88.00 and gave the company a “buy” rating in a research report on Monday. Finally, UBS Group reissued a “buy” rating and set a $90.00 price target on shares of MBX Biosciences in a report on Thursday, July 23rd. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $75.62.

MBX Biosciences Company Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.